The acquisition of MedImmune and the consolidation of our biologics capabilities into one business created one of the world's largest biologics pipelines. We are an industry leader in biotechnology, amongst other large pharmaceutical companies and biologics makes up 45% of our portfolio.
By playing an active role in the use and development of biologics, we can attack diseases that were not amenable to traditional small-molecule approaches.
Our MedImmune site in Cambridge is its European research & development site, focusing on discovering and developing antibodies and other therapeutic proteins across a range of therapy areas. Please visit the MedImmune website for more information.